Martin Fitchet
Martin Fitchet is the Chief Executive Officer of Medicines for Malaria Venture (MMV), an organization dedicated to reducing the burden of malaria worldwide. With a focus on developing new treatments and strategies to combat malaria, Fitchet emphasizes the importance of collaboration and innovation in addressing this global health challenge. Under his leadership, MMV has made significant strides in creating effective malaria medicines, particularly for vulnerable populations, such as young children and infants.
Global Media Ratings
Countries Mentioned
| Country | Mentions | Sentiment | Dominance | + Persistence | x Population | = Reach | x GDP (millions) | = Power |
|---|---|---|---|---|---|---|---|---|
| United Kingdom | 1 | 8.00 | 0.04% | +0% | 67,886,011 | 23,803 | $2,700,000 | 947$ |
| Ghana | 1 | 8.00 | 0.13% | +0% | 31,072,945 | 41,156 | $67,000 | 89$ |
| Kenya | 1 | 8.00 | 0.06% | +0% | 53,771,296 | 32,728 | $106,000 | 65$ |
| Totals | 3 | 152,730,252 | 97,687 | $2,873,000 | 1,101$ |
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Kenya:
MMV CEO Martin Fitchet said, 'Malaria is one of the world’s deadliest diseases, particularly among children.'
8
Ghana:
Martin Fitchet, CEO of MMV, says this is another important step on the road towards ending the huge toll taken by malaria.
8
United Kingdom:
Martin Fitchet, CEO of MMV, describes the approval of Coartem Baby as an important step towards ending the toll taken by malaria.
8